<i id='8878127416'><strike id='8878127416'><tt id='8878127416'><pre id='8878127416'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
BioMarin wins approval for gene therapy to treat hemophilia A 
Akero's treatment for NASH falls short in cirrhosis study 
Wildfire smoke exposes gaps in outdoor worker protections 
Bernie Sanders bashes nonprofit hospitals over their tax breaks 
Drug repurposing or repositioning? The language matters 
What the Wegovy shortage looks like for doctors — and for patients 
After affirmative action ruling, medical educators look to 'holistic review' 
Senate panel passes drug pricing bills, but drops one PBM reform 
How one medical school became remarkably diverse 
Eight reasons why you should get an updated Covid vaccine 
Continuity nursing helped my family in our darkest PICU moments 
Correcting Robert F. Kennedy Jr.'s vaccine 'facts' 
ChatGPT in medicine: STAT answers readers' burning questions 
Researchers CRISPR chickens in bid to protect them from bird flu 
Supreme Court strikes down use of affirmative action 
